Inventor
KELLY MARCUS
US16 patents
Patents
16 patentsUS10738130B2Aug 11, 2020
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
REGENERON PHARMA50 citations97
US9475875B2Oct 25, 2016
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA14 citations92
US10905784B2Feb 2, 2021
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
REGENERON PHARMA9 citations85
US10736976B2Aug 11, 2020
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
REGENERON PHARMA7 citations84
US11485793B2Nov 1, 2022
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA4 citations83
US10941208B2Mar 9, 2021
Anti-MUC16 antibodies
REGENERON PHARMA6 citations83
US11896682B2Feb 13, 2024
Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
REGENERON PHARMA3 citations74
US12053534B2Aug 6, 2024
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
REGENERON PHARMA2 citations73
US10738124B2Aug 11, 2020
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA3 citations73
US11511001B2Nov 29, 2022
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
REGENERON PHARMA3 citations72
US12564651B2Mar 3, 2026
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
REGENERON PHARMA0 citations62
US11608380B2Mar 21, 2023
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA0 citations62
US10047160B2Aug 14, 2018
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA1 citations62
US12570764B2Mar 10, 2026
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA0 citations61
US10925971B2Feb 23, 2021
Methods of treating PRLR positive breast cancer
REGENERON PHARMA1 citations61
US12144864B2Nov 19, 2024
Tubulysins and protein-tubulysin conjugates
REGENERON PHARMA0 citations52